Literature DB >> 27050521

Leukemogenic MLL-ENL Fusions Induce Alternative Chromatin States to Drive a Functionally Dichotomous Group of Target Genes.

Maria-Paz Garcia-Cuellar1, Christian Büttner2, Christoph Bartenhagen3, Martin Dugas3, Robert K Slany4.   

Abstract

MLL fusions are leukemogenic transcription factors that enhance transcriptional elongation through modification of chromatin and RNA Pol II. Global transcription rates and chromatin changes accompanying the transformation process induced by MLL-ENL were monitored by nascent RNA-seq and ChIP-seq, revealing 165 direct target genes separated into two distinct clades. ME5 genes bound MLL-ENL at the promoter, relied on DOT1L-mediated histone methylation, and coded preferentially for transcription factors, including many homeobox genes. A distinct ME3 group accumulated MLL-ENL beyond the termination site, was dependent on P-TEFb-mediated phosphorylation of RNA Pol II for transcription, and translated mainly into proteins involved in RNA biology and ribosome assembly. This dichotomy was reflected by a differential sensitivity toward small molecule inhibitors, suggesting the possibility of a combinatorial strategy for treatment of MLL-induced leukemia.
Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  DOT1L; MLL-ENL; P-TEFb; chromatin; inhibitors; leukemia

Mesh:

Substances:

Year:  2016        PMID: 27050521     DOI: 10.1016/j.celrep.2016.03.018

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  25 in total

1.  Specific patterns of H3K79 methylation influence genetic interaction of oncogenes in AML.

Authors:  Molly C Kingsley; Hongbo M Xie; Bo-Rui Chen; Simone S Riedel; Taylor Pastuer; Madelyn K Bollig; Tyler Shank; Clara Libbrecht; Sally P Stabler; Aniruddha J Deshpande; Andrew M Intlekofer; Kathrin M Bernt
Journal:  Blood Adv       Date:  2020-07-14

Review 2.  ENL: structure, function, and roles in hematopoiesis and acute myeloid leukemia.

Authors:  Jianbiao Zhou; Yvonne Ng; Wee-Joo Chng
Journal:  Cell Mol Life Sci       Date:  2018-07-31       Impact factor: 9.261

3.  The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion.

Authors:  Chunwan Lu; Amy V Paschall; Huidong Shi; Natasha Savage; Jennifer L Waller; Maria E Sabbatini; Nicholas H Oberlies; Cedric Pearce; Kebin Liu
Journal:  J Natl Cancer Inst       Date:  2017-01-28       Impact factor: 13.506

4.  Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.

Authors:  C Dafflon; V J Craig; H Méreau; J Gräsel; B Schacher Engstler; G Hoffman; F Nigsch; S Gaulis; L Barys; M Ito; J Aguadé-Gorgorió; B Bornhauser; J-P Bourquin; A Proske; C Stork-Fux; M Murakami; W R Sellers; F Hofmann; J Schwaller; R Tiedt
Journal:  Leukemia       Date:  2016-11-14       Impact factor: 11.528

5.  HoxA9 transforms murine myeloid cells by a feedback loop driving expression of key oncogenes and cell cycle control genes.

Authors:  Xiaoxia Zhong; Andreas Prinz; Julia Steger; Maria-Paz Garcia-Cuellar; Markus Radsak; Abderrazzak Bentaher; Robert K Slany
Journal:  Blood Adv       Date:  2018-11-27

6.  The efficiency of murine MLL-ENL-driven leukemia initiation changes with age and peaks during neonatal development.

Authors:  Theresa Okeyo-Owuor; Yanan Li; Riddhi M Patel; Wei Yang; Emily B Casey; Andrew S Cluster; Shaina N Porter; David Bryder; Jeffrey A Magee
Journal:  Blood Adv       Date:  2019-08-13

7.  Hematopoietic transformation in the absence of MLL1/KMT2A: distinctions in target gene reactivation.

Authors:  Yufei Chen; Patricia Ernst
Journal:  Cell Cycle       Date:  2019-06-04       Impact factor: 4.534

8.  RUNX2 regulates leukemic cell metabolism and chemotaxis in high-risk T cell acute lymphoblastic leukemia.

Authors:  Filip Matthijssens; Nitesh D Sharma; Monique Nysus; Christian K Nickl; Huining Kang; Dominique R Perez; Beatrice Lintermans; Wouter Van Loocke; Juliette Roels; Sofie Peirs; Lisa Demoen; Tim Pieters; Lindy Reunes; Tim Lammens; Barbara De Moerloose; Filip Van Nieuwerburgh; Dieter L Deforce; Laurence C Cheung; Rishi S Kotecha; Martijn Dp Risseeuw; Serge Van Calenbergh; Takeshi Takarada; Yukio Yoneda; Frederik W van Delft; Richard B Lock; Seth D Merkley; Alexandre Chigaev; Larry A Sklar; Charles G Mullighan; Mignon L Loh; Stuart S Winter; Stephen P Hunger; Steven Goossens; Eliseo F Castillo; Wojciech Ornatowski; Pieter Van Vlierberghe; Ksenia Matlawska-Wasowska
Journal:  J Clin Invest       Date:  2021-03-15       Impact factor: 14.808

9.  Exploitable metabolic dependencies in MLL-ENL-induced leukemia.

Authors:  Maria-Paz Garcia-Cuellar; Jennifer Lawlor; Martin Böttcher; Dimitrios Mougiakakos; Markus Metzler; Robert K Slany
Journal:  Blood Adv       Date:  2020-08-11

10.  Molecular synergy underlies the co-occurrence patterns and phenotype of NPM1-mutant acute myeloid leukemia.

Authors:  Oliver M Dovey; Jonathan L Cooper; Annalisa Mupo; Carolyn S Grove; Claire Lynn; Nathalie Conte; Robert M Andrews; Suruchi Pacharne; Konstantinos Tzelepis; M S Vijayabaskar; Paul Green; Roland Rad; Mark Arends; Penny Wright; Kosuke Yusa; Allan Bradley; Ignacio Varela; George S Vassiliou
Journal:  Blood       Date:  2017-08-23       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.